In addition to ibrutinib, sufferers with M-CLL, devoid of TP53 aberrations and healthy enough to tolerate FCR therapy, should be very good candidates to the latter, Using the profit staying that this procedure could be concluded in 6 months though ibrutinib needs to be taken indefinitely. This option will be significantly precious for non-compliant